Introduction: Adding covariates to linear regression models is a well-known method for reducing variability and improving the estimates of statistical analyses. In clinical trials, covariate […]
Introduction: ALS drug development is plagued by high clinical trial failure rates. Subgroup analysis is a key tool used to account for patient heterogeneity, but […]
Background: Radicava® (edaravone injection) is a US FDA-approved treatment for amyotrophic lateral sclerosis (ALS) that has been shown to slow the rate of physical functional […]
RESCUE-ALS was a Phase 2 randomized, double-blind, placebo-controlled study of CNM-Au8 as treatment for early sporadic ALS. CNM-Au8 is a suspension of clean-surfaced, catalytically active […]
RESCUE-ALS was a Phase 2 randomized, double-blind, placebo-controlled study of CNM-Au8 in early sporadic ALS, with an ongoing open-label extension (OLE) to evaluate the long-term […]
Converging lines of evidence implicate dysregulated neuronal energy metabolism as a driver of neuronal death in many neurodegenerative diseases, including Parkinson’s Disease (PD), multiple sclerosis […]
Background: Radicava® (edaravone injection) is a US FDA-approved treatment for amyotrophic lateral sclerosis (ALS) shown to slow the rate of physical functional decline. As intravenous […]
Background: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, fatal disorder for which many investigational therapies are currently under evaluation in clinical trials. Despite the […]
Background/Objectives In a phase 1 study, infusions of expanded autologous regulatory T-lymphocytes (Tregs) in combination with subcutaneous IL-2 injections were safe and well-tolerated in three […]